What is the approximate cost of one-year treatment with ibrutinib and cost analysis

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that is widely used in the treatment of various B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenstrom's macroglobulinemia (WM). The drug has been officially launched in China and has been included in the national medical insurance directory, which has greatly reduced the financial burden of some patients. However, even if it is covered by medical insurance, the overall cost of long-term treatment is still high, which is one of the factors that patients have to consider when taking medication.

According to the current domestic market price, the original drug specification of ibrutinib is 140 mg, and the price of each box of 120 pills is about 8,000 yuan. Since most treatment plans are based on a dosage of 3 pills once a day, approximately one box is required per month, and the annual treatment cost is approximately RMB 96,000. After being included in medical insurance, the reimbursement ratio varies according to different regions and policies. In some areas, reimbursement can be as high as 60%-80%, but patients still have to pay part of it out of pocket. It is conservatively estimated that the out-of-pocket amount is about 20,000 to 40,000 yuan per year.

In contrast, generic drugs in overseas markets offer more economical alternatives. For example, the price of generic versions of ibrutinib in regions such as Laos or India, such as 140mg*120 tablets, is only more than 1,000 yuan, which is significantly lower than the domestic original drug. The price of the imitation version produced by Beacon in Bangladesh is slightly higher, about 4,000 yuan. Generic drugs have the same ingredients as original drugs. Some patients choose to purchase drugs from formal overseas channels to reduce financial pressure. However, special attention must be paid to the legality and quality assurance of drug sources.
In general, the annual treatment cost of ibrutinib varies greatly depending on purchase channels and medical insurance policies. Under the coverage of medical insurance, domestic patients using original drugs will pay out-of-pocket costs ranging from tens of thousands of yuan per year; while patients who choose overseas generic drugs can reduce the cost to a few thousand to less than 10,000 yuan. Patients should weigh the efficacy, affordability, and channel safety before taking medication, and make rational medication choices under the guidance of professional doctors.
Reference: https://go.drugbank.com/drugs/